1. Home
  2. INFQ vs AGIO Comparison

INFQ vs AGIO Comparison

Compare INFQ & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Infleqtion Inc. Common Stock

INFQ

Infleqtion Inc. Common Stock

N/A

Current Price

$8.41

Market Cap

2.1B

Sector

Technology

ML Signal

N/A

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

N/A

Current Price

$31.28

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INFQ
AGIO
Founded
2007
2007
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.2B
IPO Year
2025
2013

Fundamental Metrics

Financial Performance
Metric
INFQ
AGIO
Price
$8.41
$31.28
Analyst Decision
Strong Buy
Buy
Analyst Count
7
10
Target Price
$19.57
★ $46.11
AVG Volume (30 Days)
★ 5.7M
1.2M
Earning Date
11-16-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $43,011,000.00
Revenue This Year
$38.99
$227.92
Revenue Next Year
$23.63
$96.10
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.01
$22.24
52 Week High
$21.28
$46.00

Technical Indicators

Market Signals
Indicator
INFQ
AGIO
Relative Strength Index (RSI) 40.90 45.13
Support Level $7.01 $26.57
Resistance Level $9.84 $35.77
Average True Range (ATR) 0.70 1.86
MACD 0.14 -0.19
Stochastic Oscillator 46.11 32.49

Price Performance

Historical Comparison
INFQ
AGIO

About INFQ Infleqtion Inc. Common Stock

Infleqtion Inc developing and commercializing quantum technology products as part of a full-stack platform, which currently includes offerings such as quantum sensing, quantum computing, and software. Its quantum-enabled solutions are focused on addressing the world's pressing challenges, with technologies actively deployed across some sectors today, including defense and security, artificial intelligence (AI), energy optimization, space and frontier, materials discovery, and cybersecurity.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: